Abstract: Significant shortcomings in irritable bowel syndrome (IBS) diagnosis and treatment may arise from IBS being an “umbrella” diagnosis that clusters several underlying identifiable and treatable causes for the same symptom presentation into one classification. This view is compatible with the emerging understanding that the pathophysiology of IBS is heterogeneous with varied disease mechanisms responsible for the central pathological features. Collectively, these converging views of the pathophysiology, assessment and management of IBS render the traditional diagnosis and treatment of IBS less relevant; in fact, they suggest that IBS is not a disease entity per se and posit the question “does IBS exist?” The aim of this narrative review is to explore identifiable and treatable causes of digestive symptoms, including lifestyle, environmental and nutritional factors, as well as underlying functional imbalances, that may be misinterpreted as being IBS.

Keywords: irritable bowel syndrome; lifestyle medicine; environmental medicine; nutrition

1. Introduction

Irritable bowel syndrome (IBS) is one of the most widespread functional digestive disorders with a global prevalence of 11% [1]. IBS represents a substantial burden to health status as well as the economy, with people hospitalized more frequently, consuming more medication, and missing more workdays than people without IBS [2]. Symptoms are also frequent and chronic, with a large survey demonstrating that 50% of people with IBS had had symptoms for more than ten years and 57% experienced symptoms daily [3]. Challenges facing better management of IBS include limitations of diagnostic methods and poor therapeutic options.

Current expert recommendations for the diagnosis of IBS encourage confirmation based on subjective clinical symptoms meeting the Rome IV criteria alone, with no objective evidence of the disease and minimal or no additional testing to exclude other pathology [4]. In clinical practice, however, the diagnostic guideline is often not adopted because physicians believe IBS is a diagnosis by exclusion and frequently order diagnostic tests to rule out alternative diagnoses [5]. Subsequent to diagnosis, the Bristol Stool Form Scale is used to differentiate IBS into various subtypes based on predominant symptoms—IBS with constipation, IBS with diarrhea, or IBS with mixed symptoms of constipation and diarrhea—which are used to direct treatment options [6]. No accepted biomarkers for IBS exist and novel tests have been found to perform only as good as symptom-based criteria, which is moderately well [7].

Treatment is typically based on the prevailing symptoms with antispasmodics and antidepressants used for pain, loperamide and the 5-HT(3) receptor antagonist alosetron for reducing bowel frequency, and soluble fiber for constipation predominant or mixed IBS [8]. Despite their widespread use, these treatments lack strong evidence of efficacy with less than 25% of patients reporting complete relief of any one symptom [9]. Furthermore, they have significant side-effects with many people seeking medical help or missing work, school, or social activities because of adverse events [10]. Probiotics have...
shown good evidence of efficacy and low incidence of side-effects, however, the number needed to treat (NNT) is 7 [11]. Similarly, psychological therapies including stress reduction and relaxation are beneficial and safe, yet the NNT is 4 [12]. Regardless of therapy, the response rate is typically low and does not completely resolve global symptoms [13].

Significant shortcomings in IBS diagnosis and treatment may arise from IBS being an “umbrella” diagnosis that clusters several underlying identifiable and treatable causes for the same symptom presentation into one classification [14]. This view is compatible with the emerging understanding that the pathophysiology of IBS is heterogeneous with varied disease mechanisms responsible for the central pathological features, namely alterations in gastrointestinal motility and visceral sensory function, responsible for the generation of clinical symptoms [15]. Obtaining a better understanding of each patient’s pathophysiology with clinical and molecular assessments could therefore help improve diagnosis and target different therapies to individuals most likely to benefit [16]. In a clinical setting, this heterogeneous view of IBS could be approached from the framework of functional medicine, which personalizes patient care by focusing investigative and treatment approaches on the unique state of physiological function of an individual rather than traditional histopathological or clinical definitions of disease [17].

Evidence that identification of underlying reasons for IBS-symptoms can improve patient care is provided by a clinical retrospective study that found 98% of 303 patients with diarrhea-predominant IBS (IBS-D) and functional diarrhea had an alternative explanation for their symptoms, including bile acid induced diarrhea, carbohydrate intolerance, gluten enteropathy and non-celiac gluten intolerance, and responded very well to treatments that corresponded with their new diagnosis [14]. Notably, this particular study supported the hypothesis that “IBS-D and functional diarrhea are not true clinical entities as previously thought, but a collection of different, separate medical conditions.” Similarly, another research group conducted a retrospective analysis of a biomarker test that identifies potentially treatable underlying causes of IBS in people that meet Rome III criteria and found that up to 94% have results suggesting a treatable underlying diagnosis or functional problem [18,19]. The same group also demonstrated that such testing significantly reduced medical and gastrointestinal procedural costs by improving patient care [20].

Collectively, these new and converging views of the pathophysiology, assessment and management of IBS render the traditional diagnosis and treatment of IBS less relevant; in fact, they suggest that IBS is not a disease entity per se and posit the question “does IBS exist?” Indeed, it has been proposed that cataloguing unexplained functional gastrointestinal symptoms as a distinct disease “generates lazy thinking and impedes progress” [21]. The aim of this narrative review is to explore identifiable and treatable causes of digestive symptoms, including lifestyle, environmental and nutritional factors, as well as underlying functional imbalances, that may be misinterpreted as being the syndrome of IBS (see Figure 1). Well established differential diagnosis, notably celiac disease, inflammatory bowel disease, microscopic colitis and chronic giardiasis, have been excluded from this review.
2. Lifestyle and Environmental Factors

2.1. Stress

Anxiety and depression are frequent clinical features in people presenting with IBS and may originate from the gastrointestinal disturbance in as many as two-thirds of cases [22,23]. Regardless of whether psychiatric illness precedes or follows the development of functional gastrointestinal illness, there is clearly an important contribution to gastrointestinal symptoms. For example, chronic life stress is a strong predictor of symptom intensity in people diagnosed with IBS and the absence of stress can result in symptomatic improvement over time [24]. Furthermore, low stress resilience has been found to predict IBS symptom severity [25].

Because dysregulation of the brain–gut axis can influence the main pathophysiological features of IBS, including visceral hypersensitivity, colonic motility and alterations in the gut microbiota, it could be central to the development of symptoms in some individuals [26]. Thus, psychiatric illness and chronic stress could be viewed not simply as a comorbid in patients with IBS, but important contributory factors and potential treatment targets [27].

Functional assessments of the stress response and hypothalamic–pituitary–adrenal (HPA) axis activity have been explored in patients with IBS, with some evidence to suggest elevated salivary cortisol levels at awakening [28], and serum neuropeptide Y (NPY) may be useful [29]. A greater frequency of serotonin transporter (SERT) gene variants has been found in IBS patients with a history of either depression or anxiety, and may play a functional role in digestive symptom pathogenesis [30,31]. Furthermore, the presence of at least one allele of the catechol-O-methyltransferase (COMT) Val158Met polymorphism may predict baseline symptom severity and subsequent response to stress-reduction [32,33].

Mind–body therapies such as cognitive behavioral therapy are typically utilized as indiscriminate first-line therapies for IBS, yet are still relatively effective compared to other treatments and directly improve IBS symptoms independent of effects on psychological distress [34]. They may also alter the underlying pathophysiology, with a hypnotherapy and educational intervention found to reduce visceral hypersensitivity [35]. Mind–body therapies could be targeted to patients with clinical or...
laboratory indicators of a dysregulated stress response, and there is potential for gene variants in SERT and COMT to direct treatment.

2.2. Circadian Disruption

Circadian rhythm disruption can affect several aspects of gastrointestinal function including gastrointestinal motility, visceral sensitivity, immunological function, and barrier integrity [36]. In a subgroup of people presenting with IBS, circadian rhythm disruption could contribute significantly to symptoms. Subjective and objective measures of sleep disruption have been reported to be associated with gastrointestinal symptoms [37–39]. Furthermore, circadian disruption due to shift work is associated with IBS severity independent of sleep quality [40].

Urinary 6-hydroxymelatonin, a clinical biomarker of circadian disruption, has been found to be altered in patients with IBS compared to controls and proposed to be a useful biomarker for personalized treatment with melatonin [41,42]. Melatonin therapy has been shown to result in clinical improvement when administered to people presenting with IBS and sleep disorders, independent of its effects on mood and sleep [43]. Clinical trials of melatonin in people with IBS suggest it may improve colonic transit time, reduce abdominal pain, and improve global IBS symptoms [44]. Other methods for restoring circadian disruption and melatonin production have been proposed, but not yet investigated in IBS, such as extending the dark period at night to 9 or 10 h [45].

2.3. Physical Inactivity

Physical inactivity or sedentary behaviour is known to contribute to a wide range of chronic diseases but its contribution to gastrointestinal illness is not as greatly appreciated or understood [46]. A small number of studies suggest that lack of adequate physical activity may play an important role in the development of IBS symptoms and represent an opportunity for therapeutic intervention. Clinical studies have found that increasing physical activity can improve gastric emptying, intestinal gas transit and reduce abdominal distension [47–49]. Furthermore, in patients with IBS exercise counselling and subsequent increase in physical activity, was found to significantly reduce gastrointestinal symptoms within 12-weeks and reduce psychological symptoms in the longer term [50]. Similarly, both yoga and walking reduced gastrointestinal and psychological symptoms in people with IBS [51]. Assessment of daily physical activity and the use of exercise as medicine deserves consideration in the management functional gastrointestinal disorders.

3. Nutritional Factors

3.1. Carbohydrate Restriction

Recently, the symptomatic management of IBS with diet has focused on restriction of Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and Polyols in the diet (low FODMAP diet), which works by reducing osmotic load and gas production in the distal small bowel and the proximal colon [52]. Compared to a standard western diet, a low FODMAP diet leads to a significant improvement in symptom severity, suggesting that a subgroup of patients with IBS may benefit from eating less highly fermentable carbohydrates [53]. The low FODMAP diet is typically viewed as being a short-term, second-line dietary treatment option with traditional dietary measures—such as following a regular eating pattern and limiting the intake of potential dietary triggers, such as alcohol, caffeine, spicy foods, and fat—still the first line of dietary therapy [54]. In fact, traditional dietary measures may be just as effective as a low FODMAP diet [55].

The concept of dietary carbohydrate restriction for functional gastrointestinal disorders is not entirely novel. Before the FODMAP approach gained its current popularity, it had been found that restriction of simple sugars and refined carbohydrates could result in important relief of functional digestive symptoms in some people [56–58]. Furthermore, the specific carbohydrate diet has also been reported to be of benefit [59]. It is interesting to speculate that higher intake of refined sugar and
carbohydrates could contribute to the development of IBS in some individuals. Because refined sugars can be rapidly metabolized by microbiota in the small intestine, they could play a contributory role to the development of changes in the gut microbiome that are implicated in the pathophysiology of IBS [60,61].

Identifying potential responders to carbohydrate restriction remains a challenge. Apart from testing for lactose intolerance, the FODMAP diet is based on clinical response to food elimination and re-introduction [62]. Breath testing may be useful for identifying fructose intolerance [63]. Intolerance to FODMAPs may be secondary to small intestinal bacterial overgrowth (SIBO), as determined by a positive hydrogen breath test, suggesting that a low FODMAP diet may be particularly useful for symptomatic relief in this patient group, although this is yet to be clarified [64,65]. Novel potential biomarkers that could help in the personalisation of carbohydrate restriction include sucrase-isomaltase gene variants [66].

3.2. Lactose Intolerance

Lactose intolerance, defined as gastrointestinal symptoms in an individual with lactose malabsorption, may contribute to IBS-like symptoms but could be overlooked due to challenges related to diagnosis. A higher prevalence of lactose intolerance, but not lactose malabsorption, has generally been reported in patients fulfilling criteria of IBS [67–69]. This observation was confirmed by a meta-analysis of 14 clinical trials in which lactose intolerance, but not lactose malabsorption, was found to be significantly more frequent in patients with IBS when compared to controls [70].

Identification of lactose intolerance in a clinical setting requires a positive test of lactose malabsorption such as genetic, biopsy, or H$_2$-breath tests and subsequent demonstration of an association between lactose intake and symptoms after an open-label challenge [71]. Detection of lactose malabsorption alone is not sufficient to direct dietary treatment [72]. Confirmation of lactose intolerance, however, is clinically challenging as an open-label lactose challenge may have limited accuracy in individuals with self-reported lactose intolerance [73].

Indiscriminate use of lactase enzyme therapy or a lactose-free diet in patients with IBS has not resulted in positive clinical outcomes when compared to placebo or control groups [74,75]. In contrast, clinical trials of a lactose-free diet that were initiated after identification of lactose malabsorption resulted in significant clinical improvement in some, but not all, studies [76–78]. It is possible that lactose intolerance is related to a unique pathophysiological subtype, with one study suggesting that mucosal immune activation and increased visceral sensitivity were features of lactose intolerance in IBS patients [79]. Additionally, it has been proposed that lactose intolerance is a component of a wider spectrum of intolerance to poorly absorbed carbohydrates [80].

3.3. Food Hypersensitivity

Immunologically-mediated food hypersensitivity may play a role in the development of IBS symptoms through mechanisms distinct from classic type-1 immunoglobulin E (IgE)—mediated food allergy, including a local and limited IgE-mediated reaction in the intestinal mucosa and/or IgE— independent mechanisms [81]. Studies of dietary therapy based on the elimination of suspected food sensitivities indicate that food hypersensitivity plays a role in a subgroup with IBS [82].

Elimination and re-challenge diets have been studied in patients with IBS, although evidence is mixed with some studies reporting benefit, others reporting benefit limited to subgroups of patients such as diarrhoea predominant IBS, while others have found no benefit [83–86]. In a meta-analysis of elimination and re-challenge diets, the positive clinical response ranged from 15% to 71%, however, due to limitations in study design more research is needed to clarify the role of elimination and re-challenge diets [87]. A more recent systematic review found moderate evidence for targeted elimination diets (removal of suspected symptom-provoking foods), and low evidence for generalized elimination and re-challenge diets [88].
IgG-mediated immune reactions have been proposed to play a role in the development of IBS symptoms and at least six clinical studies have found that IgG antibody-guided exclusion diets can result in modest clinical improvements in symptoms [89–94]. In contrast, one study found no benefit, although diagnostic methods varied and the diet duration was relatively short [95]. Elevated serum IgG antibodies to foods commonly associated with atopic conditions have been observed in IBS [96], although studies attempting to correlate antibodies with symptom severity [97,98], or contrast them to controls have found no association [99]. Despite controversy around the use of IgG antibody-guided exclusion diets, they appear to be a clinically useful way to identify a potential cause of symptoms and personalize dietary therapy [100].

3.4. Non-Celiac Gluten Sensitivity

Non-celiac gluten sensitivity (NCGS) is characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food in people without celiac disease or wheat allergy, and classically mimics symptoms of IBS [101]. It is unclear if it is gluten that contributes to gastrointestinal symptoms in NCGS or if symptoms are generated by other components of wheat [102]. Regardless of the underlying mechanism, a subgroup of IBS patients exhibit NCGS and experience intestinal and extra-intestinal symptoms after wheat ingestion [103,104].

A controlled trial of a gluten-containing vs. gluten-free diet in patients with diarrhea-predominant IBS without celiac disease found that exposure to gluten increases bowel movement frequency and small bowel permeability, and that this impact is greater in HLA-DQ2/8-positive genotypes [105]. Furthermore, a prospective study of a gluten-free diet in diarrhea-predominant IBS patients without celiac disease found that 71% responded well to the intervention, with greater benefit in HLA-DQ2/8-positive subjects [106]. Further supporting a role of NCGS in IBS, gluten re-challenge after a gluten-free diet was found to significantly worsen symptoms within 1 week [107].

Evidence that gluten can cause functional gastrointestinal symptoms that mimic IBS has led to the proposal that a diagnosis of IBS may delay the identification of NCGS and effective dietary therapy [108]. Clinically, NCGS currently lacks a direct biomarker and diagnosis is based on a clinical rating scale, response to a gluten-free diet, and double-placebo controlled gluten challenge [109].

3.5. Nickel-Related Intestinal Mucositis

Sensitivity to dietary nickel has been recently proposed as a cause of IBS symptoms. In a clinical study, IBS patients with a positive nickel patch test were found to respond well to a low nickel diet with significant reductions in gastrointestinal symptoms [110]. It was hypothesized by the study investigators that dietary nickel may contribute to IBS symptoms by inducing a pro-inflammatory state. In support of this theory, a low nickel diet was found to reduce inflammatory cytokines in people with gastrointestinal and cutaneous symptoms of nickel sensitivity [111].

Diagnosis of dietary nickel sensitivity can be performed with a skin or oral mucosa patch test [110,112]. All patients reporting to a gastroenterology unit with IBS symptoms and suspected sensitivity to nickel containing foods had a positive response to an oral mucosa patch test characterized by local hyperemia and/or edema, compared to no response in a control group [113]. Beyond implementation of a low nickel diet, nutritional detoxification strategies have been proposed but currently lack clinical evidence [114].

3.6. Vitamin D Deficiency

Adults and children with IBS have a high prevalence of vitamin D deficiency when compared to IBS-free controls [115,116]. Vitamin D deficiency could play a contributory role in the development of IBS due to its impact on various aspects of gastrointestinal function including mucosal inflammation [117], epithelial cell integrity [118], and the composition of the gut microbiome [119]. A case report provided initial evidence that treating vitamin D deficiency could improve gastrointestinal symptoms in IBS [120]. Subsequently, a randomized double-blind clinical trial found a significantly greater improvement in
IBS symptoms in those receiving vitamin D when compared to placebo [121]. Routinely testing for and treating vitamin D deficiency would be a logical course of action in people presenting with IBS.

4. Functional Imbalances

4.1. Exocrine Pancreatic Insufficiency

A subgroup of patients presenting with IBS have exocrine pancreatic insufficiency and respond well to treatment with digestive enzyme therapy. In a group of patients meeting criteria for diarrhea-predominant IBS exocrine pancreatic insufficiency, defined as fecal elastase-1 (FE-1) less than 100 µg/g, was present in 6.1% of patients, and subsequent pancreatic enzyme supplementation resulted in significant improvement in symptoms [122]. In this study, diarrhea-predominant IBS patients without exocrine pancreatic insufficiency were used as a control group and, in contrast, were found not to benefit from enzyme supplementation. A similar prevalence of exocrine pancreatic insufficiency of 4.1% (FE-1 <100 µg/g) was found in another study across IBS subtypes [19]. A good response to enzyme supplementation in diarrhea-predominant, and galacto-oligosaccharide intolerant IBS has been reported by other investigators [123,124].

4.2. Low-Grade Inflammation

Inflammatory biomarkers, especially C-reactive protein (CRP) and calprotectin, can be used to exclude the presence of inflammatory bowel disease (IBD) in patients presenting with symptoms consistent with IBS [125]. However, a subgroup of patients with IBS may have intestinal inflammation in the absence of IBD [126]. Low-grade intestinal inflammation is thought to play a key role in the pathophysiology of IBS, contributing to altered permeability, hypersensitivity of enteric nerves and changes in serotonin signaling [127].

Calprotectin has been proposed as a biomarker of intestinal inflammation in patients with IBS with a level higher than 50 µg/g, the absence of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), antibodies and a normal small bowel examination indicating an inflammatory IBS subtype [128].

Anti-inflammatory therapies have recently been explored in IBS, but not yet targeted to inflammatory subtypes. Clinical trials of the drug mesalazine have generally produced disappointing results, however, a subgroup of patients did appear to respond well [129,130]. In contrast, a histamine receptor H1 antagonist and extract of the anti-inflammatory herb Boswellia serrata have preliminary evidence of substantial clinical benefit [131,132]. Because food antigens are known to trigger intestinal inflammation in IBS, there is potential for the development of novel anti-inflammatory dietary interventions for patients with elevated inflammatory biomarkers, such as calprotectin. Although this concept has not yet been explored, the identification and dietary elimination of food antigens using confocal laser endomicroscopy to visualize real-time food-associated changes in the intestinal mucosa was associated with good clinical responses in patients with IBS [133].

4.3. Intestinal Permeability

Studies have suggested that a subgroup of patients with IBS have increased intestinal permeability, especially those with diarrhea-predominant symptoms [134–136]. In patients with IBS and intestinal permeability, determined by an elevated urinary lactulose/mannitol ratio, it was found that the severity of barrier dysfunction correlated with symptom severity [137]. Intestinal permeability is thought to play a central role in the development of IBS due to its contribution to low-grade intestinal inflammation and increased visceral and pain sensitivity [138].

The integrity of intestinal epithelial barrier has been proposed as a therapeutic target in IBS, although evidence for effective therapeutic interventions is currently lacking [139]. Further, the etiological factors involved in the development or intestinal permeability—such as viral, bacterial, dietary and environmental toxins—may theoretically influence the effectiveness of treatments [140]. Interestingly, there is experimental and clinical evidence to suggest that some probiotics may upregulate tight-junction...
proteins, improve the integrity of the gut epithelium, and reduce intestinal permeability [141,142]. The impact of probiotics on intestinal permeability in patients with IBS has not been well studied, but one clinical trial did find that a probiotic fermented milk drink decreased small bowel permeability and improved clinical symptoms in patients with diarrhea-predominant IBS [143].

Of clinical relevance, it was recently demonstrated that synthesis of the amino acid glutamine, a primary metabolic fuel for epithelial cells, could be impaired in diarrhea-predominant IBS, leading to reduction in tight-junction proteins and increased gut permeability [144]. Supplementation with glutamine in patients with diarrhea-predominant IBS was subsequently found to significantly reduce intestinal permeability and improved global IBS symptoms, especially diarrhea and abdominal pain [145].

4.4. Bile Acid Diarrhea

Bile acid diarrhea (BAD) is characterized by an increase in fecal excretion and change in the proportion of various bile acids in stool, which contributes to intestinal permeability, water and electrolyte secretion, and increased colonic transit [146]. From 16.9% to 35.3% of patients with IBS-D have BAD [147]. Furthermore, bile acid malabsorption, even in the absence of overt BAD, appears to contribute to diarrhea-predominant IBS [148]. BAD is typically confirmed with a therapeutic trial of bile acid binders, serum levels of $7\alpha$-hydroxy-4-cholesten-3-one (C4) or selenium homotaurocholic acid test (SeHCAT), and diagnostic confirmation can direct treatment with bile acid binders [149]. Genes controlling bile acid metabolism ($\text{KLB rs17618244}$) receptor expression ($\text{GPBAR1 rs11554825}$) are associated with colonic transit and total fecal bile acid excretion in patients with IBS and may be novel functional biomarkers [150].

Pancreatic enzyme supplementation may reduce bile acid malabsorption and improve fat malabsorption, and has been used to treat IBS-D with marked post-prandial symptoms with striking success in some cases, although the role of this therapy in clearly defined BAD is not yet established [151]. Diet is a well-established modifier of colonic bile acid concentrations, but the potential for nutritional therapy to influence bile acid malabsorption or BAD has not yet been explored [152]. Similarly, gut microbiota influence colonic bile acid concentrations and metabolism, yet gut microbiota-targeted therapies, such as probiotics and prebiotics, have not yet been studied in the clinical management of BAD [153]. More research on the therapeutic role of diet, pancreatic enzyme supplementation, probiotics and prebiotics in BAD is needed.

4.5. Chronic Constipation

Although classically differentiated from IBS, chronic constipation may mimic IBS symptoms including intermittent diarrhea. Functional constipation and IBS have overlapping clinical symptoms and share common pathophysiological mechanisms, including visceral sensitivity and alterations in serotonin signaling [154]. Fecal retention or chronic “hidden” constipation characterized by normal transit time with significantly increased fecal load in the colon has been proposed to be a cause of IBS symptoms in a subgroup of patients [155]. In a study of 252 patients with functional digestive symptoms, in particular pain, bloating and constipation with or without diarrhea, 90 were identified as having fecal loading and subsequently responded well to prokinetic treatment, diet therapy, and exercise [156]. Similarly, a clinical research group proposed that some IBS patients more correctly have “overload and overflow syndrome,” which they defined as a predominant problem of constipation with bouts of diarrhea occurring when fecal loading of the bowel reached a critical level [157]. Subgrouping IBS patients into this underlying classification using the Bristol Stool Scale and clinical symptoms was found to be a useful way to target laxative and fiber therapy and improve treatment [157].

4.6. Dysbiosis

Alterations in the gastrointestinal microbiota are central to the development of IBS and play a fundamental role in pathophysiology by activation of mucosal innate immune responses which increase
epithelial permeability, initiate nociceptive sensory pathways and dysregulate the enteric nervous system [158]. The microbiota has emerged as a therapeutic target in IBS but there is no characteristic compositional microbial alteration across patients with IBS and there is currently no well-established way to personalize gut microbiota-targeted therapies [159].

Subgrouping patients with IBS by symptoms has found some correlations with distinct microbial subtypes [160,161]. However, the association between microbial changes in IBS and its pathophysiology are not fully understood and proposing diagnostic or prognostic roles to microbiota is controversial [162]. It is interesting to speculate, however, that selectively targeting low Bifidobacteria species with prebiotics could benefit patients presenting with this microbial signature [163]. Bifidobacteria tend to be lower in patients with IBS compared to healthy controls [160,163], and declines in this species have been found to correlate with digestive symptoms, especially abdominal pain [164–166]. Clinical studies of prebiotic galactooligosaccharides [167], short-chain fructo-oligosaccharides [168,169], and partially hydrolyzed guar gum [170–173] in patients with IBS have suggested they may increase Bifidobacteria and reduce clinical symptoms.

Probiotics have been proposed as an approach for improving gut microbial composition, however a meta-analysis found no effect of probiotics on measures of composition such as α-diversity, richness, or evenness [174]. It has been suggested that the health effects of probiotics may be due to their ability to influence the metabolic function of the gut microbiota or stabilize, rather than alter, its composition [175]. Gaps in our understanding of probiotic effects are reflected in the imprecision of their clinical use, with best practice guidelines recommending that probiotic strains and dose are based on evidence of symptomatic benefit from randomized controlled trials, with a therapeutic trial for 4 weeks, and then subsequently stopping therapy and trialing another probiotic if there is a lack of clinical response [176]. Challenges facing the evolution of probiotics as a more precise therapy for IBS include the delineation of clear IBS subtypes and corresponding probiotic treatments supported by mechanism of action studies in humans and high-quality clinical trials [177]. Gene expression profiling of the peripheral blood leucocytes has recently emerged as a novel way to predict clinical probiotic response, but this technique is in its infancy [178].

Diet has a rapid and strong influence on the composition and metabolic function of the human gastrointestinal microbiota, as evidenced by associations with various dietary patterns and findings from intervention studies [179]. The low FODMAP diet has been shown to impact the gastrointestinal microbiota and related metabolome in patients with IBS. Paradoxically, the low FODMAP diet exacerbates alterations in gastrointestinal microbiota that are associated with IBS symptoms, including reduced Bifidobacteria counts [180]. However, a reduction in bacterial abundance, especially microbiota with saccharolytic potential and thus fermentation of carbohydrates, has been proposed as a central mechanism for the low FODMAP diet’s clinical effects [181]. Interestingly, the low FODMAP diet was recently shown to reduce relative abundance of bacteria involved in gas consumption, as well as an eight-fold reduction in histamine, a novel finding that may also help explain the benefits of this dietary approach [182]. Beyond the low FODMAP diet, there is a notable lack of studies of gut microbiota-targeted dietary interventions in IBS, despite their theoretical potential [183].

4.7. Small Intestinal Bacterial Overgrowth

Small intestinal bacterial overgrowth (SIBO) is defined as an abnormally high number and/or type of bacteria in the small bowel. This overgrowth is typically colonic Gram-negative aerobes and anaerobic species that ferment carbohydrate and play a role in the development of symptoms characteristic of SIBO including bloating, flatulence, abdominal discomfort and changes in stool form [184]. Perhaps not surprisingly, SIBO can mimic symptoms of IBS and case-control studies have generally found a higher prevalence of SIBO among patients with IBS (19% to 37%) compared to healthy controls (0% to 12%) [185]. This association has been suggested to be important clinically as empirical evidence suggests that treating SIBO may relieve symptoms consistent with IBS in some patients [186]. However, the link between SIBO and IBS is controversial for several reasons, including
important limitations in the reliability and accuracy of clinical diagnostic methods (breath testing),
a lack of robust data demonstrating that eradication of SIBO is clinically effective in the long term,
and evidence that the efficacy of antibiotic therapy is independent of the presence of SIBO and may
be due to non-antibiotic mechanisms [187]. The clinical management of SIBO in patients with IBS is
therefore largely empirical and not currently well supported by evidence.

Empirical management of SIBO is typically based on antibiotic therapy, of which a variety have
been used, and result in an overall rate of breath test normalization in 50% of subjects, compared with
10% for placebo [188]. Alternatives and/or adjuvants to antibiotics include dietary therapy, probiotics
and herbal therapy.

There are associations between SIBO prevalence and higher intake of carbohydrates and refined sugar
and lower intake of dietary fiber, especially insoluble fiber [60,61]. Because refined sugars can be rapidly
metabolized by microbiota in the small intestine they could play a contributory role to the development
of SIBO. Importantly, carbohydrate intolerance (lactose, fructose and sorbitol) is common among patients
with SIBO and may improve after eradication of bacterial overgrowth [64,189]. A low-fermentable
carbohydrate diet such as the low FODMAP diet, or restriction of refined carbohydrates, sugars and
gas-producing foods could be clinically useful [190].

A medical food-based elemental diet has been used for SIBO, but this approach is limited by
poor adherence and long-term safety [191]. In a retrospective study, treatment of people with IBS and
SIBO with an elemental diet (Vivonex, Nestlé Health Science) for 2 weeks normalized breath tests in
80% of people, and in non-responders a further 1 week of treatment resulted in a total response rate
of 85%. At 1-month follow-up, those who normalized their breath test showed a 66% improvement in
symptoms, compared to 11.9% in non-responders [192]. Although elemental diets limit the availability
of fermentable substrate to microbiota, they may have other effects that explain their benefits such as
reducing dietary antigen exposure and improving immunological tolerance [193].

Herbal medicines have been used as alternatives to antibiotic therapy for SIBO and appear
to be better tolerated and safer. Although herbs do have antimicrobial effects, they have several
other mechanisms of action that may explain any observed improvement in clinical symptoms
such as anti-spasmodic, pro-kinetic, immunomodulatory, anti-inflammatory, and antidiarrheal
properties. Enteric-coated peppermint oil (0.2 mL three times daily) was shown in a case-report to
normalize hydrogen breath test results and reduce IBS-like symptoms after 20 days treatment [194].
In a retrospective study, people with SIBO treated with herbal therapy (one of several different products)
were more likely to have successful treatment response, as confirmed with a negative breath-test when
compared to treatment with rifaximin (46% for herbal therapy vs. 34% for rifaximin) [195]. Additionally,
people who did not respond to rifaximin were offered either a stronger course of antibiotics or herbal
therapy, which were equally effective at eradicating SIBO (both about a 60% successful treatment).
Side-effects were fewer and less severe in those receiving herbal therapy. In addition, a novel herbal
complex containing quebrach, horse chestnut and peppermint leaf (Atrantil™, USA) developed for the
management of SIBO characterized by high methane production and IBS-C was found to improve
constipation, bloating and abdominal pain [196,197]. However, these studies did not measure the
impact of treatment on bacterial overgrowth or methane production; only clinical symptoms were
reported [196,197].

A review and meta-analysis including 22 studies of probiotic therapy for SIBO found that they
were effective overall for reducing SIBO, decreasing breath hydrogen concentration, and relieving
abdominal pain [198]. Adjuvant probiotic therapy may also improve antibiotic treatment, with one
study showing that the addition of a probiotic resulted in better resolution of SIBO compared to
antibiotic therapy alone (a negative hydrogen breath test in 93.3% with probiotics vs. 66.7% without)
as well as superior symptomatic improvement [199].
4.8. Parasitic Infection

Parasitic infection is a differential diagnosis for IBS, however, there is evidence to suggest that *Blastocystis* species infection may be overlooked as a cause of IBS symptoms in some individuals [200]. A higher prevalence of *Blastocystis* has been observed in people with IBS compared to controls in some [201–203], but not all studies [204], and *Blastocystis* species is frequently present in asymptomatic individuals. A potential reason for why *Blastocystis* might contribute to symptoms in some people but not others is that there are nine subtypes of the parasite that infect humans, some of which may be pathogenic in certain individuals [205]. Specific subtypes of *Blastocystis* may have effects that play a causative role in IBS, such as contribution to gastrointestinal dysbiosis, upregulation of pro-inflammatory cytokines, and degradation of tight junction proteins and increased intestinal permeability [206]. In support of differential associations with pathogenic *Blastocystis* subtypes, a recent meta-analysis found associations between two particular subtypes and risk for IBS symptoms [207].

Treatment of *Blastocystis* infection is controversial, with a lack of clinical trials demonstrating a resolution of symptoms after eradication in *Blastocystis*-infected IBS patients. Furthermore, there is speculation that *Blastocystis* is not a cause of IBS but an indicator of intestinal dysfunction or dysbiosis [208]. Conventional treatment of *Blastocystis* infection is typically antibiotic monotherapy with the success in eradicating the parasite ranging from anywhere between 0% and 100% in various studies, and there are no trials in patients with IBS [209]. One group reported 60% eradication and an improvement in IBS symptoms with a unique antibiotic therapy regime in a pilot study [210]. Furthermore, there is some clinical evidence that herbal therapy with emulsified oil of Oregano (Origanum vulgare) [211], and the probiotic Saccharomyces boulardii [212] may eradicate *Blastocystis* infection but they have not yet been investigated in *Blastocystis*-infected patients with IBS.

It is probable that several other parasites, as well as bacteria and viruses, could contribute to symptoms of IBS but clear evidence of causal roles is often lacking for candidate pathogens and requires more research [213]. Similar to *Blastocystis*, there is some evidence, albeit conflicting, to suggest *Dientamoeba fragilis* may be an overlooked and treatable cause of IBS-like symptoms. Although a statistically significant association has not been reported between *D. fragilis* and IBS [204] there are prospective studies and case reports of *D. fragilis* eradication resulting in clinical improvement in patients previously diagnosed with IBS and presenting with typical symptoms of diarrhea, constipation, abdominal pain, bloating, and flatulence [214–216]. In contrast, one study found no association between eradication of *D. fragilis* and clinical response in IBS patients [217]. The data implicating *D. fragilis* in IBS is thus limited to a small number of conflicting studies and requires clarification [218].

5. Discussion

The available evidence suggests that the symptoms of IBS are frequently due to identifiable and treatable underlying causes including lifestyle, environmental and nutritional factors, as well as underlying functional imbalances, that may be misinterpreted as being the syndrome of IBS. IBS, therefore, could be considered a set of symptoms that require further investigation and not a disease per se. This view is consistent with the heterogeneous pathophysiology of IBS in that different causative factors would influence different physiological mechanisms, although the resultant symptoms may still be consistent with classification as IBS. Compatible with this view is the notion that an individual’s genetics, including the genetics of their microbiome, may interact with lifestyle, environmental and nutritional factors in unique ways that give rise to the symptoms of IBS.

Creating a distinction between the symptom-based diagnosis of IBS and the underlying causes that give rise to those symptoms may aid progress in disentangling the clinical overlap between IBS and other functional gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and functional dyspepsia (FD). Overlap between these conditions is very common, yet pathophysiological reasons for their co-occurrence in the same patient are not well understood [219]. A better understanding of the pathophysiological origin of functional gastrointestinal symptoms related to IBS, GERD and FD may help improve treatment options [220]. In support of this hypothesis, there is empirical evidence
to suggest that identification and treatment of a shared pathophysiological origin, H. pylori infection, may resolve overlapping symptoms of IBS, GERD, FD and/or erosive esophagitis in some cases [221]. It seems reasonable to suggest that personalized treatment of underlying pathophysiological causes of functional gastrointestinal symptoms could improve outcomes across a wide range of symptom-based diagnosis, not only IBS.

In a clinical setting, the identification of the underlying causes of symptoms in a person with IBS would help personalize treatment and target therapies to those most likely to respond (Table 1), although it should be emphasized that many of the clinical and biochemical investigations and management approaches discussed require clarification before translation to clinical practice. Also, of relevance to clinical trials, patient subgroups based on clinical and biochemical assessments could help direct personalised therapies or identify treatment responders. Importantly, multiple factors may be involved in the development of IBS symptoms and these will vary from person to person, thus a comprehensive, systems-based approach to management that leverages guidance from individual clinical presentations and laboratory biomarkers may represent the best path forward [222].
Table 1. Summary of factors that may explain irritable bowel symptoms.

<table>
<thead>
<tr>
<th>Contributing Factor</th>
<th>Mechanisms</th>
<th>Clinical and Biochemical Investigations</th>
<th>Potential Management and Treatment Approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circadian disruption</td>
<td>Circadian rhythm disruption can affect several aspects of gastrointestinal function including gastrointestinal motility, visceral sensitivity, immunological function, and barrier integrity.</td>
<td>Questioning around sleep patterns and electric light-at-night exposure. Salivary melatonin.</td>
<td>Extending the dark period. Regular sleep patterns.</td>
</tr>
<tr>
<td>Physical inactivity</td>
<td>Clinical studies have found that increasing physical activity can improve gastric emptying, intestinal gas transit and reduce abdominal distension.</td>
<td>Tracking physical activity levels. Activity tracker step count.</td>
<td>Exercise counselling. Yoga. Walking.</td>
</tr>
<tr>
<td>Lactose intolerance</td>
<td>Unabsorbed lactose in the intestine can increase osmotic load and intestinal water content in addition to undergoing fermentation to produce short chain fatty acids and gas including hydrogen and methane, which may cause or aggravate symptoms in susceptible individuals.</td>
<td>Positive test of lactose malabsorption (genetic, biopsy, or H₂-breath test) and subsequent open-label lactose challenge.</td>
<td>Lactase enzyme therapy. Low-lactose or lactose-free diet.</td>
</tr>
<tr>
<td>Food hypersensitivity</td>
<td>Immunologically mediated food hypersensitivity may play a role in the development of gastrointestinal symptoms via a local and limited IgE-mediated reaction in the intestinal mucosa and/or IgE-independent mechanisms.</td>
<td>Dietary elimination and re-challenge. IgG antibodies to foods.</td>
<td>Elimination and re-challenge diet. IgG antibody-guided exclusion diet.</td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Contributing Factor</th>
<th>Mechanisms</th>
<th>Clinical and Biochemical Investigations</th>
<th>Potential Management and Treatment Approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-celiac gluten sensitivity</td>
<td>People with NCGS have evidence of immune activation (measured with increased serum levels of soluble CD14), leaky gut (lipopolysaccharide-binding protein and antibody reactivity to bacterial LPS and flagellin) and intestinal damage (fatty acid-binding protein 2).</td>
<td>Clinical rating scale, response to a gluten-free diet, and double-placebo controlled gluten challenge. HLA-DQ2/8 gene variants.</td>
<td>Gluten-free diet.</td>
</tr>
<tr>
<td>Nickel-related intestinal mucositis</td>
<td>In nickel sensitive people, exposure results in elevated levels of IFNy, IL-5, and IL-13 in the supernatants of peripheral blood mononuclear cell cultures stimulated with nickel, suggesting a pro-inflammatory effect.</td>
<td>Positive nickel patch test.</td>
<td>Low nickel diet.</td>
</tr>
<tr>
<td>Vitamin D deficiency</td>
<td>Vitamin D deficiency could contribute to mucosal inflammation, impaired epithelial cell integrity, and the alterations in the composition of the gut microbiome.</td>
<td>Serum 25-hydroxy vitamin D.</td>
<td>Sunlight exposure. Vitamin D3 supplementation.</td>
</tr>
<tr>
<td>Exocrine pancreatic insufficiency</td>
<td>Impaired digestion of food may increase antigenic load and/or contribute to postprandial osmotic diarrhea.</td>
<td>Clinical symptoms of postprandial osmotic diarrhea, or galacto-oligosaccharide intolerance. Fecal elastase-1 (FE-1).</td>
<td>Digestive enzyme therapy.</td>
</tr>
<tr>
<td>Low-grade inflammation</td>
<td>Low-grade intestinal inflammation contributes to altered permeability, hypersensitivity of enteric nerves and changes in serotonin signaling.</td>
<td>Fecal calprotectin.</td>
<td>Low antigenic/elimination diet. Anti-inflammatory diet. Anti-inflammatory herbal medicines, such as Boswellia serrata.</td>
</tr>
<tr>
<td>Bile acid malabsorption</td>
<td>An increase in the fecal excretion and change in the proportion of the various bile acids in stool contributes to intestinal permeability, water and electrolyte secretion, and increased colonic transit.</td>
<td>Therapeutic trial of bile acid binders. Serum 7α-hydroxy-4-cholesten-3-one. Selenium homoaurocholic acid test. KLB rs17618244 and GPBAR1rs11554825 gene variants.</td>
<td>Bile acid binders. Pancreatic enzyme therapy. Diet that minimizes bile acid production and/or excretion. Probiotics. Prebiotics.</td>
</tr>
</tbody>
</table>
### Table 1. Cont.

<table>
<thead>
<tr>
<th>Contributing Factor</th>
<th>Mechanisms</th>
<th>Clinical and Biochemical Investigations</th>
<th>Potential Management and Treatment Approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic constipation</td>
<td>Functional constipation is associated with visceral sensitivity and alterations in serotonin signaling.</td>
<td>The Bristol Stool Scale.</td>
<td>Laxatives. Fiber therapy.</td>
</tr>
<tr>
<td>Parasitic infection or overgrowth</td>
<td>Specific subtypes of <em>Blastocystis</em> species may contribute to dysbiosis, upregulate pro-inflammatory cytokines, and degrade tight junction proteins and increase intestinal permeability. <em>D. fragilis</em>-infection may result in inflammatory changes and intestinal permeability in the gut mucosa.</td>
<td>Comprehensive stool parasitology, including <em>Blastocystis</em> species and <em>D. fragilis</em>.</td>
<td>Antibiotic therapy. Emulsified oil of Oregano. Saccharomyces boulardii.</td>
</tr>
</tbody>
</table>
Funding: The author received no grants or other financial support for this review.

Acknowledgments: The author thanks Deanna Minich for valuable comments on the draft manuscript and the anonymous peer-reviewers for their important and helpful critique.

Conflicts of Interest: The author has received consultancy fees from Pure Encapsulations (Sudbury, MA, USA).

References


26. Muscatello, M.R.; Bruno, A.; Scimeca, G.; Pandolfo, G.; Zoccali, R.A. Role of negative a... [CrossRef]


Gastrointest. Disord. 2019, 1


46. Pedersen, B.K.; Saltin, B. Exercise as medicine—evidence for prescribing exercise as therapy in 26 diarrhoea-predominant irritable bowel patients. QJM 1988, 149, 171–179. [CrossRef]


Gastrointest. Disord. 2019, 1


125. Menees, S.B.; Powell, C.; Kurlander, J.; Goel, A.; Chey, W.D. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol. 2015, 110, 444–454. [CrossRef] [PubMed]

126. Martin-Viñas, J.J.; Quigley, E.M. Immune response in irritable bowel syndrome: A systematic review of 


129. Barbara, G.; Cremon, C.; Annese, V.; Basilisco, G.; Bazzoli, F.; Bellini, M.; Benedetti, A.; Benini, L.; Bossa, F.; Buldrini, P.; et al. Randomised controlled trial of mesalazine in IBS. Gut 2016, 65, 82–90. [CrossRef]


146. Camilleri, M. Bile Acid diarrhea: Prevalence, pathogenesis, and therapy. *Gut Liver* 2015, 9, 332–339. [CrossRef]


© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).